

Table 6. Comparison between dupilumab and ESS for the treatment of nasal polyps.

Treatment	Endpoints	LS Mean Change from Baseline (\pm SE)	Relative Change (%)
ESS 24 weeks	NCS	-1.9 ± 0.09	-66
	Loss of smell score	-1.0 ± 0.13	-44
	SNOT-22 score	-33.3 ± 1.8	-59
	SIT-40	8.5 ± 5.2	+36
ESS 52 weeks	NCS	-2.1 ± 0.13	-72
	Loss of smell score	-1.2 ± 0.16	-43
	SNOT-22 score	-33.9 ± 3.04	-59
	SIT-40	7.0 ± 8.6	+36
Dupilumab 24 weeks	NCS	-1.34 ± 0.07	-59
	Loss of smell score	-1.41 ± 0.07	-52
	SNOT-22 score	-30.43 ± 1.54	-63
	SIT-40	11.26 ± 0.67	+77
Dupilumab 52 weeks	NCS	-1.35 ± 0.07	-54
	SNOT-22 score	-29.84 ± 1.63	-59

SNOT-22 = 22-item Sino-Nasal Outcome Test; LS = least square; NCS = nasal congestion score; SIT-40 = smell identification test-40; SE = standard error.